Institute Of Hematology & Blood Diseases Hospital, China

This early-phase study tests a new treatment called CT1194D CAR-T cells in 20 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety and find the best dose, while also measuring how well it shrinks tumors. Par…

This early-phase study tests a new treatment called GC012F for people with rheumatoid arthritis that hasn't improved with standard therapies. Nine adults will receive a single infusion of their own modified immune cells. The main goal is to check safety and see how long the cells…

This early-phase study tests a new treatment called CY-219 CAR-T cells in 18 people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. The main goals are to check…

This study compares two standard first treatments for severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. One treatment is a stem cell transplant from a half-matched donor, and the other is a combination of drugs that suppress the immune sys…

This study tests whether the drug gecacitinib can help people with myelofibrosis (a serious bone marrow disease) who are getting a stem cell transplant. The goal is to reduce complications like graft-versus-host disease and relapse. About 39 adults aged 18-75 will take the drug b…

This study tests a drug called daratumumab in people with refractory aplastic anemia, a serious condition where the bone marrow stops making enough blood cells. The trial has two phases: first to check safety and find the right dose, then to see if it improves blood cell counts. …

This study aims to reduce CMV infections in stem cell transplant patients by using a scoring system that measures immune recovery. The system will help doctors decide when to stop antiviral medication (letermovir) after transplant. The trial will enroll 1114 participants and trac…

This study tests whether adding venetoclax to azacitidine as maintenance therapy helps keep acute myeloid leukemia (AML) in remission longer. About 788 patients aged 14 to 74 who are in their first remission after initial treatment will receive either azacitidine alone or azaciti…

This study tests whether adding two targeted drugs (olverembatinib or gecacitinib) to standard chemotherapy and venetoclax can improve outcomes for adults with a high-risk leukemia called Ph-like ALL. About 30 participants will receive treatment based on their specific genetic ch…

This study tests if luspatercept can improve anemia in 20 adults with blood cancers who had a stem cell transplant. The goal is to reduce the need for red blood cell transfusions. Participants receive the drug and are monitored for blood counts and side effects.

This early-phase trial tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard therapies. The treatment uses donor immune cells (γδT cells) that are engineered to target and attack faulty B cells. The main goa…

This early-phase study tests a time-limited combination of three drugs (ibrutinib, bendamustine, and rituximab) in people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to find the safest dose and see if a fixed course of treatment can control the disease wi…

This study looks back at medical records of 500 people with immune thrombocytopenia (ITP) to see how they are treated in everyday clinics across China. It includes both treated and untreated patients, and aims to understand which treatments work best and how the disease progresse…